Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jul 24 04:00PM ET
0.3565
Dollar change
+0.0205
Percentage change
6.10
%
Index- P/E- EPS (ttm)-0.33 Insider Own10.59% Shs Outstand79.58M Perf Week-9.36%
Market Cap28.37M Forward P/E- EPS next Y-0.15 Insider Trans-0.74% Shs Float71.15M Perf Month-6.18%
Income-15.53M PEG- EPS next Q-0.04 Inst Own5.02% Short Float2.06% Perf Quarter-32.10%
Sales0.00M P/S- EPS this Y65.00% Inst Trans-0.71% Short Ratio2.35 Perf Half Y11.06%
Book/sh-0.08 P/B- EPS next Y-10.71% ROA-276.90% Short Interest1.47M Perf Year-79.97%
Cash/sh0.01 P/C36.37 EPS next 5Y- ROE-1121.89% 52W Range0.13 - 1.90 Perf YTD30.59%
Dividend Est.- P/FCF- EPS past 5Y10.57% ROI- 52W High-81.24% Beta0.36
Dividend TTM- Quick Ratio0.18 Sales past 5Y0.00% Gross Margin- 52W Low166.04% ATR (14)0.04
Dividend Ex-Date- Current Ratio0.18 EPS Y/Y TTM50.40% Oper. Margin0.00% RSI (14)43.88 Volatility8.23% 9.56%
Employees29 Debt/Eq- Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price2.00
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q61.87% Payout- Rel Volume0.69 Prev Close0.34
Sales Surprise- EPS Surprise28.57% Sales Q/Q- EarningsMay 14 AMC Avg Volume624.50K Price0.36
SMA20-3.69% SMA50-18.07% SMA200-0.68% Trades Volume431,743 Change6.10%
Date Action Analyst Rating Change Price Target Change
Feb-04-21Upgrade Maxim Group Hold → Buy $12
Nov-17-20Downgrade Maxim Group Buy → Hold
Dec-19-16Reiterated Maxim Group Buy $5 → $6
Dec-22-15Reiterated Maxim Group Buy $14 → $5
Today 08:30AM
Jul-01-24 06:00AM
Jun-27-24 09:15AM
Jun-26-24 08:00AM
Jun-20-24 06:00AM
12:01PM Loading…
Jun-14-24 12:01PM
May-20-24 06:00AM
May-14-24 10:53PM
04:30PM
May-01-24 07:31AM
Apr-16-24 06:30PM
Apr-11-24 06:00AM
Apr-10-24 06:00AM
Apr-09-24 06:00AM
Apr-08-24 06:00AM
08:05AM Loading…
Apr-01-24 08:05AM
Feb-27-24 06:30AM
Feb-23-24 06:00AM
Feb-13-24 06:30AM
Dec-27-23 09:30AM
Dec-26-23 07:30AM
Dec-20-23 09:00AM
Dec-07-23 08:40AM
Nov-20-23 08:10AM
Nov-17-23 07:00AM
Nov-15-23 01:53PM
03:29AM
Nov-14-23 07:05AM
Nov-08-23 08:00AM
Nov-07-23 06:00AM
07:00AM Loading…
Oct-24-23 07:00AM
Oct-23-23 10:05AM
Oct-18-23 08:01AM
06:00AM
Oct-02-23 07:00AM
Sep-27-23 10:48PM
06:15PM
07:00AM
Sep-26-23 12:17PM
Sep-25-23 08:13AM
Aug-18-23 08:34AM
Aug-15-23 03:11AM
Aug-14-23 07:05AM
Aug-07-23 04:05PM
Jul-17-23 09:15AM
Jul-12-23 07:00AM
Jul-07-23 07:00AM
Jun-20-23 09:06AM
Jun-16-23 07:00AM
Jun-06-23 06:00AM
May-23-23 11:35AM
May-19-23 07:30AM
May-18-23 08:55AM
May-17-23 02:41PM
May-15-23 07:05AM
May-09-23 06:00AM
Apr-24-23 07:00AM
Apr-07-23 07:30AM
Apr-05-23 07:46PM
Apr-04-23 09:12AM
Mar-30-23 07:05AM
Mar-27-23 09:15AM
06:00AM
Mar-21-23 08:18AM
Jan-10-23 07:00AM
Jan-05-23 07:30AM
Jan-04-23 07:30AM
Dec-27-22 06:00AM
Dec-12-22 07:00AM
Nov-17-22 06:56AM
06:15AM
Nov-16-22 11:28AM
Nov-14-22 07:05AM
Nov-10-22 11:01AM
08:30AM
Nov-07-22 04:10PM
06:00AM
Oct-20-22 06:00AM
Oct-07-22 12:00PM
Oct-04-22 06:00AM
Sep-15-22 06:00AM
Aug-30-22 08:20AM
Aug-17-22 10:16AM
Aug-15-22 07:05AM
Aug-01-22 06:00AM
May-31-22 06:00AM
May-24-22 07:10AM
May-16-22 08:00AM
07:05AM
May-12-22 08:02AM
May-04-22 06:00AM
May-03-22 06:00AM
May-02-22 06:00AM
Apr-04-22 06:20AM
Mar-28-22 09:00AM
07:05AM
Mar-23-22 12:56PM
Mar-14-22 06:00AM
Feb-28-22 04:09PM
Feb-15-22 07:30AM
Brainstorm Cell Therapeutics, Inc. is a biotechnology company, which develops and commercializes autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis, Progressive Multiple Sclerosis, Alzheimer's disease, and other neurodegenerative diseases. Its pipeline, NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and improve neurological function. The company was founded by Irit Arbel on September 22, 2000 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dagher Ibrahim B.Chief Medical OfficerJul 19 '24Sale0.3563,00022,0690Jul 24 04:05 PM
Lindborg StacyCo-Chief Executive OfficerSep 01 '23Buy1.7711,50020,402181,500Sep 05 05:16 PM